Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 7
Submit an article Journal homepage
126
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases

Suehiro Sakaguchi The University of Tokushima, The Institute for Enzyme Research, Division of Molecular Neurobiology, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan +81 88 633 7438; +81 88 633 7440; [email protected]
,
Daisuke Ishibashi Nagasaki University Graduate School of Biomedical Sciences, Department of Molecular Microbiology and Immunology, Sakamoto 1-12-4, Nagasaki 852-8523, Japan
&
Haruo Matsuda Hiroshima University, Graduate School of Biosphere Science, Laboratory of Immunology, Department of Molecular and Applied Bioscience, 1-4-4 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8528, Japan
Pages 907-917 | Published online: 11 Jun 2009

Bibliography

  • Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95(23):13363-83
  • DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am J Pathol 1995;146(4):785-811
  • Duffy P, Wolf J, Collins G, et al. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290(12):692-3
  • Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;1(8009):478-9
  • Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985;313(12):731-3
  • Thadani V, Penar PL, Partington J, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg 1988;69(5):766-9
  • Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977;197(4307):943-60
  • Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997;389(6650):498-501
  • Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389(6650):448-50, 526
  • Collee JG, Bradley R, Liberski PP. Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: part 2. Folia Neuropathol 2006;44(2):102-10
  • Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278(5336):245-51
  • Available from: http://www.cjd.ed.ac.uk/figures.htm
  • Available from: http://niah.naro.affrc.go.jp/disease/bse/count.html
  • Williams ES. Chronic wasting disease. Vet Pathol 2005;42(5):530-49
  • Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363(9407):417-21
  • Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364(9433):527-9
  • Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006;368(9552):2061-7
  • Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008;22(1):58-69
  • Brandel JP, Preece M, Brown P, et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 2003;362(9378):128-30
  • Cervenakova L, Goldfarb LG, Garruto R, et al. Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 1998;95(22):13239-41
  • Wadsworth JD, Asante EA, Desbruslais M, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004;306(5702):1793-6
  • Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006;5(5):393-8
  • Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203(3):733-9
  • Prusiner SB. Molecular biology of prion diseases. Science 1991;252(5012):1515-22
  • Oesch B, Westaway D, Walchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985;40(4):735-46
  • Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73(7):1339-47
  • Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993;90(22):10608-12
  • Sakaguchi S, Katamine S, Shigematsu K, et al. Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 1995;69(12):7586-92
  • Manson JC, Clarke AR, McBride PA, et al. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 1994;3(4):331-40
  • Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302(5646):871-4
  • Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53(3):325-35
  • Yokoyama T, Kimura KM, Ushiki Y, et al. In vivo conversion of cellular prion protein to pathogenic isoforms, as monitored by conformation-specific antibodies. J Biol Chem 2001;276(14):11265-71
  • Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996;380(6575):639-42
  • Nishida N, Tremblay P, Sugimoto T, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest 1999;79(6):689-97
  • Gambetti P, Parchi P, Petersen RB, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol 1995;5(1):43-51
  • Neufeld MY, Josiphov J, Korczyn AD. Demyelinating peripheral neuropathy in Creutzfeldt-Jakob disease. Muscle Nerve 1992;15(11):1234-9
  • Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993;362(6420):543-6
  • Muller WE, Ushijima H, Schroder HC, et al. Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 1993;246(3):261-7
  • Hetz C, Russelakis-Carneiro M, Maundrell K, et al. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003;22(20):5435-45
  • Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129(Pt 9):2241-65
  • Sakaguchi S. Recent developments in therapeutics for prion diseases. Expert Opin Ther Patents 2008;18(1):35-59
  • De Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 2008;3(3):e1888
  • Gauczynski S, Nikles D, El-Gogo S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006;194(5):702-9
  • Rainov NG, Tsuboi Y, Krolak-Salmon P, et al. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007;7(5):713-26
  • Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008;15(5):458-64
  • Available from: http://www.ctu.mrc.ac.uk/studies/cjd.asp
  • Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004;17(3):158-63
  • Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62(5):714-8
  • Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412(6848):739-43
  • Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001;98(16):9295-9
  • Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev 1999;12(3):429-44
  • Kaneko K, Peretz D, Pan KM, et al. Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci USA 1995;92(24):11160-4
  • Horiuchi M, Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999;18(12):3193-203
  • Kim CL, Karino A, Ishiguro N, et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 2004;85(Pt 11):3473-82
  • Perrier V, Solassol J, Crozet C, et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 2004;89(2):454-63
  • Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997;3(12):1383-8
  • Hundt C, Peyrin JM, Haik S, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001;20(21):5876-86
  • Gauczynski S, Peyrin JM, Haik S, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001;20(21):5863-75
  • Leucht C, Simoneau S, Rey C, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003;4(3):290-5
  • Ludewigs H, Zuber C, Vana K, et al. Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther 2007;5(4):613-30
  • Vana K, Zuber C, Nikles D, Weiss S. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell Mol Neurobiol 2007;27(1):107-28
  • Vana K, Zuber C, Pflanz H, et al. LRP/LR as an alternative promising target in therapy of prion diseases, Alzheimer's disease and cancer. Infect Disord Drug Targets 2009;9(1):69-80
  • Zuber C, Ludewigs H, Weiss S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet Microbiol 2007;123(4):387-93
  • Miyamoto K, Nakamura N, Aosasa M, et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem Biophys Res Commun 2005;335(1):197-204
  • Medical Res Council (GB). US2006280745; 2006
  • White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422(6927):80-3
  • Song CH, Furuoka H, Kim CL, et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 2008;89(Pt 6):1533-44
  • Lefebvre-Roque M, Kremmer E, Gilch S, et al. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 2007;1(3):198-206
  • Kagoshima Univ (JP); Search Inst Juridical Foundati (JP); Sugimura Kazuhisa (JP); Nakashima Toshihiro (JP). WO2006046344; 2006
  • Donofrio G, Heppner FL, Polymenidou M, et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79(13):8330-8
  • Campana V, Zentilin L, Mirabile I, et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2008;418(3):507-15
  • Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008;16(3):481-6
  • Mandel RJ, Manfredsson FP, Foust KD, et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006;13(3):463-83
  • Tenenbaum L, Chtarto A, Lehtonen E, et al. Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 2004;6(Suppl 1):S212-22
  • Li ZJ, Wang RZ. rAAV vector-mediated gene therapy for experimental ischemic stroke. Neurol India 2008;56(2):116-21
  • Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999;73(11):9446-55
  • Halbert CL, Rutledge EA, Allen JM, et al. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000;74(3):1524-32
  • Lo WD, Qu G, Sferra TJ, et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999;10(2):201-13
  • Mastakov MY, Baer K, Symes CW, et al. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 2002;76(16):8446-54
  • Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004;303(5663):1514-6
  • Zuber C, Mitteregger G, Pace C, et al. Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 2007;1(3):207-12
  • Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008;45(1):144-51
  • Weiss Stefan (DE); Little Melvyn (DE); Knackmuss Stefan (DE); Rey Clemence (DE); Roettgen Peter (DE); Buettner Claudia (DE); Reusch Uwe (DE). WO2005035580; 2005
  • Zuber C, Mitteregger G, Schuhmann N, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008;89(Pt 8):2055-61
  • Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 2003;113(1):49-60
  • Genoud N, Ott D, Braun N, et al. Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am J Pathol 2008;172(5):1287-96

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.